GLP-1 &
Metabolic Response
The most comprehensive GLP-1 genetic report available. 9 genes, 20+ variants, 3 clinical dimensions -- will it work, why you eat the way you do, and which drug fits your biology. Includes two exclusive pathways found in no other consumer GLP-1 test: leptin resistance (LEP/LEPR) and drug interaction watch (CYP2D6).
⚠ Research Use Only. Not FDA-cleared or approved. Not intended to diagnose, treat, cure, or prevent any disease. Always discuss findings with a licensed healthcare provider.
See a fully rendered example -- real RSIDs, peer-reviewed citations, and clinical action guidance -- before you commit.
RSIDs analyzed in this panel
Representative variants. Full report includes all associated loci with genotyped values, effect sizes, and clinical interpretation.
Supporting literature
Phan A. et al. (2025) Obesity -- semaglutide 2.4mg n=112, GLP1R rs6923761 sex-modified response. Nature 2026 GWAS (N=27,885) -- first genome-wide GLP-1 RA predictors; GIPR rs1800437 tirzepatide-specific signal. Dawed et al. Lancet Diabetes & Endocrinology 2023 (n=4,571 across 5 RCTs). Godschall et al. Nature 2026 -- GLP-1 central amygdala reward circuit mechanism. Zorn et al. Nature Medicine 2025 -- MC4R cardiovascular lipid independence (n=7,719). Hu et al. Endocr Connect 2025 -- leptin resistance review. Jayathilaka et al. Clin Pharmacol Drug Dev 2025 -- ARRB1 & CYP2D6 indirect interaction.
Layer 1: Will It Work?
GLP1R encodes the receptor that semaglutide and all GLP-1 drugs bind to. Carriers of rs6923761 show 1.64%/month weight loss vs. 1.04% in non-carriers in a prospective semaglutide study -- and 0% of women with the AA genotype were non-responders. ARRB1 controls receptor internalization and biased agonism, explaining why some patients plateau earlier and why dose escalation helps some but not others. These two genes determine the fundamental biological ceiling of GLP-1 efficacy for you specifically.
Layer 2: Why You Eat the Way You Do
FTO rs9939609 AA carriers consume ~350 more kcal after a standardized meal because their brains keep responding to food cues even after eating -- confirmed by fMRI. A 2026 Nature paper confirmed GLP-1 drugs suppress exactly this neural circuit via the central amygdala. MC4R rs17782313 variants affect not just appetite but cardiovascular lipid risk independently of body weight (7,719-person Nature Medicine 2025 study). LEP/LEPR variants drive leptin resistance -- the silent background factor explaining why some patients need higher doses or combination approaches. AuraGen is the only GLP-1 test that includes this pathway.
Layer 3: Which Drug, What Risk
GIPR rs1800437 determines how much benefit you get from tirzepatide's dual GLP-1 + GIP mechanism -- and whether the GIP arm elevates vomiting risk (15x odds when combined with GLP1R effect allele, Nature 2026). CTRB1 rs7202877 is included as a tolerability and incretin-pathway flag with full transparency: it has strong DPP-4 inhibitor evidence but GLP-1 RA efficacy is non-significant (OR 1.12, p=0.84). CYP2D6 status generates a personalized drug interaction watch list for commonly co-prescribed antidepressants and beta-blockers whose absorption is altered by GLP-1's effect on gastric emptying -- a safety feature found in no other GLP-1 genetic report.
How to read this report
Every variant row shows two badges: a genotype status badge (CARRIER / RISK ALLELE / REFERENCE / NOT DETECTED) and an evidence level badge (Level A = strong, multiple studies or CPIC/FDA guideline; Level B = moderate, single study or mechanistic). AuraGen is transparent where evidence is strong vs. emerging -- we never present all variants as equivalent predictors. This is the only GLP-1 genetic test that discloses evidence grades variant-by-variant.
This report is for Research Use Only and is not FDA-cleared, FDA-approved, or CE-IVD certified. Polygenic risk scores and pharmacogenomic findings reflect statistical associations from published peer-reviewed GWAS studies. Results are not diagnostic and do not constitute medical advice. Always consult a licensed physician, genetic counselor, or pharmacist before acting on any finding. © 2026 AuraGen Wellness · auragenwellness.com
- ✓Layer 1 -- Will It Work? GLP1R (4 variants) + ARRB1 -- direct receptor response genes
- ✓Layer 2 -- Why You Eat: FTO rs9939609 (fMRI-validated satiety), MC4R rs17782313 (CV module), CNR1 (cravings), LEP/LEPR (leptin resistance) -- EXCLUSIVE
- ✓Layer 3 -- Drug Match & Risk: GIPR rs1800437 (tirzepatide-specific), CTRB1 (tolerability), CYP2D6 (drug interaction watch) -- EXCLUSIVE
- ✓Drug match module: semaglutide vs. tirzepatide vs. retatrutide recommendation based on your genotype
- ✓Interpretation key: Level A / Level B evidence grading with full transparency disclosures
- ✓Powered by Nature 2026 GWAS (N=27,885) + Lancet Diabetes & Endocrinology 2023 (n=4,571) + 7 peer-reviewed citations
⚠ Research Use Only · Not FDA cleared